Despite Slowing Disease Progression, Amgen's Lung Cancer Studies Show High Liver Toxicity
Results from two Amgen studies on Lumakras for lung cancer showed its ability to slow disease progression, although combining it with immunotherapy increased the risk for TRAEs.
Source: biospace.com